Villarroel and colleagues (2011) described a pancreatic cancer patient that had a long-lasting response to mitomycin C (MMC, a crosslinking agent) treatment and whose tumor was deficient for PALB2 [61]. This evidence concerns the gene PALB2 and pancreatic neoplasm.